Literature DB >> 30958379

Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.

Tessandra Stewart1, Min Shi1, Aanchal Mehrotra1, Patrick Aro1, David Soltys1, Kathleen F Kerr2, Cyrus P Zabetian3,4, Elaine R Peskind5,6, Peggy Taylor7, Leslie M Shaw8, John Q Trojanowski9,10, Jing Zhang1.   

Abstract

BACKGROUND: Neurodegenerative diseases require characterization based on underlying biology using biochemical biomarkers. Mixed pathology complicates discovery of biomarkers and characterization of cohorts, but inclusion of greater numbers of patients with different, related diseases with frequently co-occurring pathology could allow better accuracy. Combining cohorts collected from different studies would be a more efficient use of resources than recruiting subjects from each population of interest for each study.
OBJECTIVE: To explore the possibility of combining existing datasets by controlling pre-analytic variables in the Alzheimer's Disease Neuroimaging Initiative (ADNI) and Parkinson's Progression Markers Initiative (PPMI) studies.
METHODS: Cerebrospinal fluid (CSF) was collected and processed from 30 subjects according to both the ADNI and PPMI protocols. Relationships between reported levels of Alzheimer's disease (AD) and Parkinson's disease (PD) biomarkers in the same subject under each protocol were examined.
RESULTS: Protocol-related differences were observed for Aβ, but not t-tau or α-syn, and trended different for p-tau and pS129. Values of α-syn differed by platform. Conversion of α-syn values between ADNI and PPMI platforms did not completely eliminate differences in distribution. DISCUSSION: Factors not captured in the pre-analytical sample handling influence reported biomarker values. Assay standardization and better harmonized characterization of cohorts should be included in future studies of CSF biomarkers.

Entities:  

Keywords:  Alzheimer’s disease; Parkinson’s disease; amyloid-β; tau; α-Synuclein

Year:  2019        PMID: 30958379      PMCID: PMC6513710          DOI: 10.3233/JAD-190069

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  40 in total

1.  Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

Authors:  M Sjögren; H Vanderstichele; H Agren; O Zachrisson; M Edsbagge; C Wikkelsø; I Skoog; A Wallin; L O Wahlund; J Marcusson; K Nägga; N Andreasen; P Davidsson; E Vanmechelen; K Blennow
Journal:  Clin Chem       Date:  2001-10       Impact factor: 8.327

2.  Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

Authors:  Niki S M Schoonenboom; Cees Mulder; Hugo Vanderstichele; Evert-Jan Van Elk; Astrid Kok; Gerard J Van Kamp; Philip Scheltens; Marinus A Blankenstein
Journal:  Clin Chem       Date:  2004-11-11       Impact factor: 8.327

3.  Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides.

Authors:  Piotr Lewczuk; Georg Beck; Hermann Esselmann; Ralf Bruckmoser; Rüdiger Zimmermann; Magdalena Fiszer; Mirko Bibl; Juan Manuel Maler; Johannes Kornhuber; Jens Wiltfang
Journal:  Clin Chem       Date:  2006-02       Impact factor: 8.327

4.  Imaging amyloid deposition in Lewy body diseases.

Authors:  S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

5.  Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition.

Authors:  Elaine R Peskind; Ge Li; Jane Shofer; Joseph F Quinn; Jeffrey A Kaye; Chris M Clark; Martin R Farlow; Charles DeCarli; Murray A Raskind; Gerard D Schellenberg; Virginia M-Y Lee; Douglas R Galasko
Journal:  Arch Neurol       Date:  2006-07

6.  Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry.

Authors:  R L Hamilton
Journal:  Brain Pathol       Date:  2000-07       Impact factor: 6.508

7.  Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease.

Authors:  C F Lippa; M L Schmidt; V M Lee; J Q Trojanowski
Journal:  Ann Neurol       Date:  1999-03       Impact factor: 10.422

8.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Authors:  Tero Tapiola; Irina Alafuzoff; Sanna-Kaisa Herukka; Laura Parkkinen; Päivi Hartikainen; Hilkka Soininen; Tuula Pirttilä
Journal:  Arch Neurol       Date:  2009-03

Review 9.  CSF markers for incipient Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

10.  The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.

Authors:  Lidia Glodzik-Sobanska; Elizabeth Pirraglia; Miroslaw Brys; Susan de Santi; Lisa Mosconi; Kenneth E Rich; Remigiusz Switalski; Leslie Saint Louis; Martin J Sadowski; Frank Martiniuk; Pankaj Mehta; Domenico Pratico; Raymond P Zinkowski; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-10-24       Impact factor: 4.673

View more
  2 in total

1.  The Association of CSF sTREM2 With Cognitive Decline and Its Dynamic Change in Parkinson's Disease: Analysis of the PPMI Cohort.

Authors:  Qixiong Qin; Hengming Wan; Danlei Wang; Jingyi Li; Yi Qu; Jingwei Zhao; Jiangting Li; Zheng Xue
Journal:  Front Aging Neurosci       Date:  2022-06-16       Impact factor: 5.702

Review 2.  Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation.

Authors:  Ernesto S Nakayasu; Marina Gritsenko; Paul D Piehowski; Yuqian Gao; Daniel J Orton; Athena A Schepmoes; Thomas L Fillmore; Brigitte I Frohnert; Marian Rewers; Jeffrey P Krischer; Charles Ansong; Astrid M Suchy-Dicey; Carmella Evans-Molina; Wei-Jun Qian; Bobbie-Jo M Webb-Robertson; Thomas O Metz
Journal:  Nat Protoc       Date:  2021-07-09       Impact factor: 17.021

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.